Ratio Therapeutics
↗Boston, USA
Ratio Therapeutics is a clinical-stage biotechnology company focused on developing next-generation radiopharmaceuticals for cancer treatment. The company utilizes two proprietary technology platforms: Trillium™, which allows for the fine-tuning of a drug's pharmacokinetics (PK), and Macropa™, a high-affinity chelator for alpha-emitting isotopes like Actinium-225.
By combining these platforms, Ratio aims to create 'tunable' radiotherapies that maximize tumor delivery while minimizing radiation exposure to healthy tissues. The company is currently advancing a pipeline of targeted alpha therapies (TATs) and diagnostic agents through strategic partnerships and internal development.
CLASSIFICATION
SIZE & FINANCIALS
Employees:1-50
Revenue:Pre-revenue
Founded:2021
Ownership:private
Status:operating
FUNDING
Stage:Series B
Total Raised:$90M
Investors:Schusterman Family Investments, Duquesne Family Office, Pura Vida Investments, Candid Healthcare, Jackalope Ventures, Pavilion Capital
PIPELINE
Stage:Phase 1
Lead Drug Stage:Phase 1
Modalities:Radiopharmaceuticals, Targeted Alpha Therapy (TAT), Small molecule, Peptide
Active Trials:1
Trial Phases:Phase 1: 1
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Bayer (Collaboration on Actinium-225 therapies), Lantheus (Development of FAP-targeted diagnostics), Merck / MSD (Research collaboration for novel radiopharmaceuticals), NorthStar Medical Radioisotopes (Supply agreement for Ac-225)
COMPETITION
Position:Emerging
Competitors:RayzeBio (BMS), Point Biopharma (Eli Lilly), Novartis (Pluvicto/Lutathera), Mariana Oncology (Novartis), Actinium Pharmaceuticals, AdvanCell
LEADERSHIP
Key Executives:
Jack Hoppin, PhD - CEO & Co-founder
John Babich, PhD - CSO & Co-founder
Scientific Founders:Jack Hoppin, John Babich
Board Members:Jack Hoppin, John Babich, Representatives from Schusterman Family Investments
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Ratio Therapeutics. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.